PURPOSE: Established guidelines recommend evaluation for hereditary cancer syndromes in patients younger than 50 years diagnosed with colorectal cancer (CRC). This group has been well described in the literature; however, patients diagnosed as adolescents and young adults are not well represented in CRC studies. Here, we define the clinical profile, including the extent of hereditary cancer syndromes and family history of cancer, in patients diagnosed with CRC at age 35 or younger. PATIENTS AND METHODS: We reviewed patients who underwent genetic counseling at our institution during 5 years (2009 to 2013). Data were collected regarding demographics, clinicopathologic information, tumor and genetic testing, and family history. Patients with an identified hereditary cancer syndrome were compared with those without a syndrome. RESULTS: Of the 193 patients with evaluable data, 35% had an identifiable hereditary cancer syndrome, including 23 with Lynch syndrome, 22 with mutation-negative Lynch syndrome, 16 with familial adenomatous polyposis, two with constitutional mismatch repair deficiency, two with biallelic MUTYH mutations, and one with Li-Fraumeni syndrome. Patients without a hereditary syndrome more frequently presented with metastatic disease, whereas patients with a syndrome were more likely to present at earlier stages and to have a family history of cancer. Nevertheless, a substantial proportion of the hereditary syndromes (19%) were diagnosed in individuals with no family history of the disease. CONCLUSION: We conclude that patients diagnosed with CRC at age 35 years or younger should receive genetic counseling regardless of their family history and phenotype.
PURPOSE: Established guidelines recommend evaluation for hereditary cancer syndromes in patients younger than 50 years diagnosed with colorectal cancer (CRC). This group has been well described in the literature; however, patients diagnosed as adolescents and young adults are not well represented in CRC studies. Here, we define the clinical profile, including the extent of hereditary cancer syndromes and family history of cancer, in patients diagnosed with CRC at age 35 or younger. PATIENTS AND METHODS: We reviewed patients who underwent genetic counseling at our institution during 5 years (2009 to 2013). Data were collected regarding demographics, clinicopathologic information, tumor and genetic testing, and family history. Patients with an identified hereditary cancer syndrome were compared with those without a syndrome. RESULTS: Of the 193 patients with evaluable data, 35% had an identifiable hereditary cancer syndrome, including 23 with Lynch syndrome, 22 with mutation-negative Lynch syndrome, 16 with familial adenomatous polyposis, two with constitutional mismatch repair deficiency, two with biallelic MUTYH mutations, and one with Li-Fraumeni syndrome. Patients without a hereditary syndrome more frequently presented with metastatic disease, whereas patients with a syndrome were more likely to present at earlier stages and to have a family history of cancer. Nevertheless, a substantial proportion of the hereditary syndromes (19%) were diagnosed in individuals with no family history of the disease. CONCLUSION: We conclude that patients diagnosed with CRC at age 35 years or younger should receive genetic counseling regardless of their family history and phenotype.
Authors: Christina E Bailey; Chung-Yuan Hu; Y Nancy You; Brian K Bednarski; Miguel A Rodriguez-Bigas; John M Skibber; Scott B Cantor; George J Chang Journal: JAMA Surg Date: 2015-01 Impact factor: 14.766
Authors: Daniel T Chang; Rish K Pai; Lisa A Rybicki; Michael A Dimaio; Maneesha Limaye; Priya Jayachandran; Albert C Koong; Pamela A Kunz; George A Fisher; James M Ford; Mark Welton; Andrew Shelton; Lisa Ma; Daniel A Arber; Reetesh K Pai Journal: Mod Pathol Date: 2012-04-06 Impact factor: 7.842
Authors: Asad Umar; C Richard Boland; Jonathan P Terdiman; Sapna Syngal; Albert de la Chapelle; Josef Rüschoff; Richard Fishel; Noralane M Lindor; Lawrence J Burgart; Richard Hamelin; Stanley R Hamilton; Robert A Hiatt; Jeremy Jass; Annika Lindblom; Henry T Lynch; Païvi Peltomaki; Scott D Ramsey; Miguel A Rodriguez-Bigas; Hans F A Vasen; Ernest T Hawk; J Carl Barrett; Andrew N Freedman; Sudhir Srivastava Journal: J Natl Cancer Inst Date: 2004-02-18 Impact factor: 13.506
Authors: Nicole de Rosa; Miguel A Rodriguez-Bigas; George J Chang; Jula Veerapong; Ester Borras; Sunil Krishnan; Brian Bednarski; Craig A Messick; John M Skibber; Barry W Feig; Patrick M Lynch; Eduardo Vilar; Y Nancy You Journal: J Clin Oncol Date: 2016-07-18 Impact factor: 44.544
Authors: Adam S Gordon; Elisabeth A Rosenthal; David S Carrell; Laura M Amendola; Michael O Dorschner; Aaron Scrol; Ian B Stanaway; Shannon DeVange; James D Ralston; Hana Zouk; Heidi L Rehm; Eric Larson; David R Crosslin; Kathy A Leppig; Gail P Jarvik Journal: Am J Hum Genet Date: 2019-08-15 Impact factor: 11.025
Authors: Neil Vasan; Maria Ignez Braghiroli; Alexander N Shoushtari; Richard Kinh Gian Do; Marcia Edelweiss; Ali Shamseddine; Walid Faraj; Deborah Mukherji; Ali Haydar; Ashwaq Olayan; Fouad Sabatin; Rita Assi; Imane El Dika; Leonard B Saltz; Ghassan K Abou-Alfa; Eileen M O'Reilly Journal: J Gastrointest Oncol Date: 2017-06
Authors: Elena M Stoffel; Erika Koeppe; Jessica Everett; Peter Ulintz; Mark Kiel; Jenae Osborne; Linford Williams; Kristen Hanson; Stephen B Gruber; Laura S Rozek Journal: Gastroenterology Date: 2017-11-14 Impact factor: 22.682
Authors: Y Nancy You; Ester Borras; Kyle Chang; Brandee A Price; Maureen Mork; George J Chang; Miguel A Rodriguez-Bigas; Brian K Bednarski; Funda Meric-Bernstam; Eduardo Vilar Journal: Dis Colon Rectum Date: 2019-04 Impact factor: 4.585
Authors: Mohamed E Salem; Francesca Battaglin; Richard M Goldberg; Alberto Puccini; Anthony F Shields; David Arguello; W Michael Korn; John L Marshall; Axel Grothey; Heinz-Josef Lenz Journal: Oncologist Date: 2019-12-17